With EWA Government Systems and Spiramed (Pty) Ltd., US-based Wound Management Technologies has obtained registration of the wound care collagen product CellerateRX(R) in the region and has also obtained the necessary NAPPI codes, which are a pre-requisite for any billable health product in South Africa.

In addition, CellerateRX(R) is registered with various South African insurance companies and is an authorized product for reimbursement.

The CellerateRX(R) products will be distributed by Spiramed (Pty) Ltd.

Wound Management Technologies' subsidiary, Wound Care Innovations, LLC, has the exclusive worldwide distribution rights to CellerateRX(R) and has a representative agreement with EWA Government Systems to engage CellerateRX(R) distributors in Africa and other international markets.

“We are pleased to be working with Wound Care Innovations, LLC and Spiramed (Pty) Ltd. to introduce CellerateRX(R) to the African market,” said Lynn Adcock, Director of Africa Strategic Planning, EWA Government Systems, Inc.

“We have received positive responses from multiple African countries with the clinical use of this product.”

Cathy Bradshaw, President of Wound Care Innovations, added: “The recurring worldwide acceptance of CellerateRX(R) evidenced by our recent expansion into Central America and now South Africa, shows that our international sales efforts are well placed and that CellerateRX(R) has unique benefits in wound care.

“EWA has worked diligently to get the CellerateRX(R) products into this market and we look forward to continued market expansion with them.”

CellerateRX(R) is FDA approved for market for all acute and chronic wounds, except 3rd degree burns.

Source: http://www.wmgtech.com